D K Hyslop
Overview
Explore the profile of D K Hyslop including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wong E, Sonders M, Amara S, Tinholt P, Piercey M, Hoffmann W, et al.
Biol Psychiatry
. 2000 May;
47(9):818-29.
PMID: 10812041
Background: Reboxetine is a potent antidepressant, with efficacy comparable to that of imipramine, desipramine, and fluoxetine, and has improved side-effect profile. The basis of its efficacy and improved tolerability is...
2.
Piercey M, Hyslop D, Hoffmann W
Brain Res
. 1997 Jul;
762(1-2):19-28.
PMID: 9262154
Previous studies have demonstrated that both direct- and indirect-acting dopamine (DA) receptor agonists excite type II neurons in the anterior caudate (CN) by stimulation of DA receptors belonging to the...
3.
Heier R, Dolak L, Duncan J, Hyslop D, Lipton M, Martin I, et al.
J Med Chem
. 1997 Feb;
40(5):639-46.
PMID: 9057850
The imidazoquinoline (R)-5,6-Dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine [(R)-3] is a potent dopamine agonist when tested in animals but surprisingly shows very low affinity in in vitro binding assays. When incubated with mouse or monkey...
4.
Piercey M, Hoffmann W, Smith M, Hyslop D
Eur J Pharmacol
. 1996 Sep;
312(1):35-44.
PMID: 8891576
Pramipexole, an amino-benzathiazole [(S)-4,5,6,7-tetrahydro-N-6-propyl-2, 6-benzothiazolediamine dihydrochloride monohydrate] direct-acting dopamine receptor agonist effective in treating Parkinson's disease, bound selectively and with high affinity to dopamine D2-like receptors, with highest affinity at...
5.
Piercey M, Hyslop D, Hoffmann W
Brain Res
. 1996 Jan;
706(2):249-58.
PMID: 8822364
Using chloral hydrate anesthetized rats, dopamine (DA) agonists were evaluated for their systemic effects on firing rates of DA neurons in rat substantia nigra pars compacta (SNPC) and postsynaptic type...
6.
Yocca F, Eison A, Hyslop D, Ryan E, Taylor D, Gianutsos G
Life Sci
. 1991 Jan;
49(24):1777-85.
PMID: 1682780
The effect of continuous treatment with the selective 5-HT1A agonist gepirone upon 5-HT2-mediated behavior and cortical 5-HT2 receptor binding sites was examined in naive rats or rats receiving noradrenergic (DSP4)...
7.
Sethy V, Hyslop D
Neuropharmacology
. 1990 Feb;
29(2):185-8.
PMID: 2330074
The role of muscarinic receptors in the regulation of (3H)-acetylcholine (3H-Ach) release from the hippocampus was investigated with the irreversible cholinergic agonist BM-123 (N-[4(2-chloroethylmethylamino)-2-butynyl]2-pyrrolidone). Pretreatment with BM-123 had no significant...
8.
Hyslop D, WESTRICK M, Shukla U, Taylor D
Ther Drug Monit
. 1989 Jan;
11(3):295-303.
PMID: 2728088
Tiospirone has demonstrated preclinical activities that predict utility as an antipsychotic drug which lacks the potential to produce extrapyramidal side effects. Indeed, human safety trials after single and multiple dose...
9.
Yocca F, Hyslop D, Smith D, Maayani S
Eur J Pharmacol
. 1987 Jun;
137(2-3):293-4.
PMID: 2886356
No abstract available.
10.
Taylor D, Allen L, ASHWORTH E, Becker J, Hyslop D, RIBLET L
Neuropharmacology
. 1981 May;
20(5):513-6.
PMID: 7242871
No abstract available.